This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carnemolla, B. Articles by Zardi, L. Search for Related Content PubMed PubMed Citation Articles by Carnemolla, B. Articles by Zardi, L.

(American Journal of Pathology. 1999;154:1345-1352.)
© 1999 American Society for Investigative Pathology

Technical Advance

Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody

Barbara Carnemolla^*, Patrizia Castellani^*, Marco Ponassi^*, Laura Borsi^*, Stefania Urbini^*, Guido Nicolo^*, Alessandra Dorcaratto^§, Giuseppe Viale^§, Greg Winter, Dario Neri and Luciano Zardi^*

From the Laboratory of Cell Biology and Laboratory of Anatomic Pathology,^*
Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; the Cambridge Centre for Protein Engineering,
MRC Centre, Cambridge, United Kingdom; the Institut fur Molekularbiologie und Biophysik,
ETH Honggerberg, Zürich, Switzerland; and the Institute of Neurosurgery,^§
University of Genoa Medical School, Genoa, Italy.

Tenascin-C exists in several polymorphic isoforms due to alternative splicing of nine fibronectin-like type III repeats. Large Tenascin-C isoforms are present in almost all normal adult tissues but are upregulated in fetal, regenerating, and neoplastic tissues. Here, we report a human antibody fragment, TN11, derived from a phage library with high affinity for the spliced repeat C and demonstrate that this repeat is undetectable in normal adult tissues, barely detectable or undetectable in breast, lung and gastric carcinomas, meningioma, and low grade astrocytoma, but extremely abundant in high grade astrocytoma (grade III and glioblastoma), especially around vascular structures and proliferating cells. The antibody appears to have potential for development of a therapeutic agent for patients with high grade astrocytoma.

This article has been cited by other articles:

				T. von Lukowicz, M. Silacci, M. T. Wyss, E. Trachsel, C. Lohmann, A. Buck, T. F. Luscher, D. Neri, and C. M. Matter Human Antibody Against C Domain of Tenascin-C Visualizes Murine Atherosclerotic Plaques Ex Vivo J. Nucl. Med., April 1, 2007; 48(4): 582 - 587. [Abstract] [Full Text] [PDF]

				A. von Holst, U. Egbers, A. Prochiantz, and A. Faissner Neural Stem/Progenitor Cells Express 20 Tenascin C Isoforms That Are Differentially Regulated by Pax6 J. Biol. Chem., March 23, 2007; 282(12): 9172 - 9181. [Abstract] [Full Text] [PDF]

				M. Silacci, S. S. Brack, N. Spath, A. Buck, S. Hillinger, S. Arni, W. Weder, L. Zardi, and D. Neri Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo Protein Eng. Des. Sel., October 1, 2006; 19(10): 471 - 478. [Abstract] [Full Text] [PDF]

				S. S. Brack, M. Silacci, M. Birchler, and D. Neri Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res., May 15, 2006; 12(10): 3200 - 3208. [Abstract] [Full Text] [PDF]

				M. Ferrari, M. Cremonesi, M. Bartolomei, L. Bodei, M. Chinol, M. Fiorenza, G. Tosi, and G. Paganelli Dosimetric Model for Locoregional Treatments of Brain Tumors with 90Y-Conjugates: Clinical Application with 90Y-DOTATOC J. Nucl. Med., January 1, 2006; 47(1): 105 - 112. [Abstract] [Full Text] [PDF]

				J. Smith, R. E. Kontermann, J. Embleton, and S. Kumar Antibody phage display technologies with special reference to angiogenesis FASEB J, March 1, 2005; 19(3): 331 - 341. [Abstract] [Full Text] [PDF]

				J. P. Venables Aberrant and Alternative Splicing in Cancer Cancer Res., November 1, 2004; 64(21): 7647 - 7654. [Abstract] [Full Text] [PDF]

				L. Borsi, E. Balza, B. Carnemolla, F. Sassi, P. Castellani, A. Berndt, H. Kosmehl, A. Biro, A. Siri, P. Orecchia, et al. Selective targeted delivery of TNF{alpha} to tumor blood vessels Blood, December 15, 2003; 102(13): 4384 - 4392. [Abstract] [Full Text] [PDF]

				T. Tsunoda, H. Inada, I. Kalembeyi, K. Imanaka-Yoshida, M. Sakakibara, R. Okada, K. Katsuta, T. Sakakura, Y. Majima, and T. Yoshida Involvement of Large Tenascin-C Splice Variants in Breast Cancer Progression Am. J. Pathol., June 1, 2003; 162(6): 1857 - 1867. [Abstract] [Full Text] [PDF]

				P. Castellani, L. Borsi, B. Carnemolla, A. Biro, A. Dorcaratto, G. L. Viale, D. Neri, and L. Zardi Differentiation between High- and Low-Grade Astrocytoma Using a Human Recombinant Antibody to the Extra Domain-B of Fibronectin Am. J. Pathol., November 1, 2002; 161(5): 1695 - 1700. [Abstract] [Full Text] [PDF]

				C. Halin, L. Zardi, and D. Neri Antibody-Based Targeting of Angiogenesis Physiology, August 1, 2001; 16(4): 191 - 194. [Abstract] [Full Text] [PDF]

				H. Maseruka, A. Ridgway, A. Tullo, and R. Bonshek Developmental Changes in Patterns of Expression of Tenascin-C Variants in the Human Cornea Invest. Ophthalmol. Vis. Sci., December 1, 2000; 41(13): 4101 - 4107. [Abstract] [Full Text]

				A. PAU, A DORCARATTO, G L VIALE, P CASTELLANI, A SIRI, and L ZARDI Oncofetal matrix glycoproteins in cerebral arteriovenous malformations and neighbouring vessels J. Neurol. Neurosurg. Psychiatry, January 1, 2000; 68(1): 101 - 102. [Full Text]